A Research Guide for
PCOS & Early Menopause

PCOS is diagnosed using the Rotterdam criteria, the internationally accepted standard endorsed by the 2023 guidelines. You need at least two of three features after ruling out other conditions:

1. Irregular or absent ovulation — irregular, infrequent, or absent periods (cycles longer than 35 days, fewer than 8 cycles per year, or absent periods for 3+ months)
2. Excess androgens — either clinical signs (hirsutism, severe acne, androgenic hair loss) or elevated androgen levels on blood tests (total testosterone, free testosterone, or DHEA-S)
3. Polycystic ovarian morphology — enlarged ovaries with 20+ follicles on ultrasound (updated from the previous threshold of 12) or elevated Anti-Müllerian Hormone (AMH) levels (which can now be used as an alternative to ultrasound)

Your doctor must also rule out other conditions that mimic PCOS, including thyroid disorders, non-classic congenital adrenal hyperplasia (17-OHP test), elevated prolactin, and Cushing syndrome.

Medication alert: Valproate (valproic acid — brand names Depakote, Epilim; used for epilepsy and bipolar disorder) can cause PCOS-like symptoms including irregular periods, elevated androgens, and weight gain in many women who take it. If you take valproate and have PCOS-like symptoms, tell your prescribing doctor — in some cases, switching to a different medication (such as lamotrigine or levetiracetam) may help, if that is safe for your condition.

Important for adolescents: Diagnosing PCOS during adolescence is challenging because irregular periods and acne are common during normal puberty. The 2023 guidelines recommend that ultrasound should not be used for PCOS diagnosis within 8 years of the first period. In teens, diagnosis requires both persistent irregular periods and clear evidence of excess androgens (blood tests preferred over clinical signs). If there is uncertainty, the guidelines recommend using the term “at risk for PCOS” with reassessment later.

POI is diagnosed based on:

• Absent or irregular periods for 4+ months in a woman under 40
• Elevated FSH (follicle-stimulating hormone) > 25 IU/L (this threshold dates to the 2015/2016 ESHRE guideline; older references used 40 IU/L). The 2024 ESHRE/ASRM/IMS guideline update allows the diagnosis on a single elevated FSH (with menstrual disturbance), rather than requiring two separate measurements — though a repeat or AMH is still often used when the picture is uncertain.

Once diagnosed, your doctor should investigate the cause with additional testing:

• Karyotype — to check for Turner syndrome or other chromosomal differences
• FMR1 premutation testing — fragile X-associated POI (important for family planning counseling)
• Autoimmune panel — thyroid antibodies, adrenal antibodies (21-hydroxylase antibodies), and possibly celiac screening. Autoimmune causes are the most common identifiable cause of POI
• AMH level — very low or undetectable levels confirm significantly reduced ovarian reserve
• Bone density scan (DEXA) — baseline assessment since low estrogen increases osteoporosis risk

Note: POI is not the same as “early menopause” in a strict medical sense. In POI, ovarian function may fluctuate — spontaneous ovulation and even pregnancy can occur in about 5–10% of cases. However, both conditions share the same long-term health risks from estrogen deficiency, and the management approach is similar.

Not all PCOS is the same. The Rotterdam criteria identify four distinct phenotypes, each with different metabolic risk profiles:

• Phenotype A (Classic): All three criteria present (irregular cycles + excess androgens + polycystic ovaries). Highest metabolic risk.
• Phenotype B (Classic without PCOM): Irregular cycles + excess androgens. High metabolic risk.
• Phenotype C (Ovulatory): Excess androgens + polycystic ovaries with regular cycles. Moderate metabolic risk.
• Phenotype D (Non-hyperandrogenic): Irregular cycles + polycystic ovaries without excess androgens. Lower metabolic risk but still significant.

Understanding your phenotype helps your doctor tailor your treatment and monitoring plan. Women with Phenotype A or B need the most intensive metabolic screening.

You can help ensure a thorough evaluation by bringing:

• Period tracking data: Dates, duration, and flow for the last 6–12 months (apps like Clue, Flo, or a simple calendar work well)
• Symptom diary: Note acne, unwanted hair growth, hair thinning, mood changes, weight changes, hot flashes, night sweats, vaginal dryness
• Family history: Particularly diabetes, PCOS, early menopause, thyroid disease, autoimmune conditions, infertility, or heart disease
• Current medications and supplements
• Your questions: Written down so you don’t forget in the moment

• Which diagnostic criteria are you using for my PCOS diagnosis, and which phenotype do I have?
• Have you ruled out other causes of my symptoms (thyroid, adrenal, prolactin)?
• What do my hormone levels (testosterone, FSH, AMH, DHEA-S) mean?
• If I might have POI, what additional testing do I need (karyotype, FMR1, autoimmune)?
• Should I have a baseline OGTT (glucose tolerance test) and lipid panel?
• How often should I have follow-up blood work and monitoring?
• Should I see a reproductive endocrinologist or other specialist?

Diet: No single “PCOS diet” has been proven superior. The 2023 guidelines recommend general healthy eating principles for all women with PCOS, regardless of weight. Key evidence-based approaches include:

• A balanced, anti-inflammatory eating pattern (Mediterranean-style diets have good evidence)
• Reducing refined carbohydrates and added sugars to improve insulin sensitivity
• Adequate protein and fiber to support satiety
• Avoiding very restrictive or fad diets — these are counterproductive and unsustainable

Exercise: The guidelines recommend at least 150 minutes per week of moderate-intensity activity (or 75 minutes vigorous), plus muscle-strengthening activities 2+ days per week. Any movement you enjoy and can sustain is beneficial. Exercise improves insulin sensitivity independently of weight loss.

Weight management: For overweight women with PCOS, a 5–10% reduction in body weight significantly improves hormonal and metabolic outcomes. However, PCOS itself makes weight loss more difficult due to insulin resistance and hormonal factors. This is a biological challenge, not a personal failure. Weight management should always be approached sensitively, without stigma, and with professional support.

Combined oral contraceptives (COCs): First-line medication for menstrual regulation and treating excess androgens (acne, hirsutism) in women not trying to conceive. They protect the endometrium from overgrowth caused by unopposed estrogen in anovulatory cycles. The 2023 guidelines recommend the lowest effective dose of ethinyl estradiol. Some progestins (drospirenone, cyproterone acetate) have additional anti-androgen properties.

Progestins: For women who cannot take combined contraceptives (e.g., migraine with aura, blood clot risk), cyclic progestin therapy (e.g., medroxyprogesterone acetate for 10–14 days each month) provides endometrial protection.

Spironolactone: An anti-androgen medication used for hirsutism and acne, typically at 50–200 mg daily. It takes 6–12 months to see full effect on hair growth. Must be used with reliable contraception as it can cause feminization of male fetuses (teratogenic). Important: stop spironolactone at least 3 months before trying to conceive to ensure complete elimination before early embryogenesis. Requires periodic monitoring of potassium levels (every 4–6 weeks initially, then annually once stable). Also monitor for low blood pressure, especially in the first weeks.

Endometrial protection: Women with PCOS who are not ovulating regularly need either COCs, cyclic progestins, or a hormonal IUD (such as Mirena) to protect the uterine lining from excess thickening, which increases the risk of endometrial hyperplasia and, rarely, endometrial cancer.

Metformin: Widely used for PCOS, particularly for insulin resistance and metabolic risk. The 2023 guidelines recommend metformin as an adjunct to lifestyle when metabolic features are prominent, or when COCs are contraindicated or not tolerated. Typical dose: 1,500–2,000 mg daily (extended-release formulation reduces gastrointestinal side effects). Metformin may also modestly improve ovulation in some women.

Inositol: Myo-inositol (4 g/day) + D-chiro-inositol (in a 40:1 ratio) has moderate evidence for improving insulin sensitivity, ovulation, and androgen levels. European studies are particularly supportive. It is well-tolerated and can be used alongside other treatments. The 2023 guidelines recognize it as having potential benefits but note the evidence is not yet as strong as for metformin.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide): These are emerging as potentially transformative treatments for PCOS with obesity and severe insulin resistance. Studies show significant weight loss (12–15%+) and improvements in metabolic markers. The 2025 Lancet Commission highlighted GLP-1 RA potential in PCOS management. Important: These are not yet approved specifically for PCOS and must not be used during pregnancy. Discuss with your doctor whether off-label use may be appropriate for you.

Vitamin D: Deficiency is common in PCOS and may worsen insulin resistance. Supplementation to achieve normal levels (30+ ng/mL) is recommended if deficient.

Excess hair growth (hirsutism), acne, and scalp hair thinning are among the most distressing PCOS symptoms. Effective treatments include:

• Anti-androgen medications: Spironolactone is most commonly used in the US; cyproterone acetate (Diane-35) in Europe/Australia — note the EMA restricts it to moderate-to-severe acne/hirsutism only, not routine contraception. These take 6–12 months for full effect on hair growth.
• Eflornithine cream (Vaniqa): Applied topically to slow facial hair growth. Works while being used; hair returns if stopped.
• Laser hair removal: Most effective for dark hair on lighter skin; multiple sessions needed. Can provide long-lasting reduction. Best combined with anti-androgen therapy.
• Electrolysis: Permanent hair removal. Effective for all hair and skin types but time-intensive.
• Acne treatments: COCs with anti-androgenic progestins, topical retinoids, and sometimes isotretinoin for severe cases (requires strict contraception).
• Hair loss: Minoxidil (topical) can help scalp hair thinning. Anti-androgens may slow progression.

Cosmetic concerns are medically valid and should be addressed as part of PCOS care — they significantly affect quality of life and mental health.

PCOS can feel isolating, especially when symptoms are visible (acne, hair growth) or when weight management is a constant struggle. Partners and family members can help by:

• Educating yourself about PCOS — understanding that it is a real medical condition, not a lifestyle choice
• Avoiding comments about weight, food choices, or appearance — even well-meaning suggestions can feel like blame
• Supporting healthy habits together — cooking balanced meals, exercising together, and making lifestyle changes a shared project
• Being patient with mood changes — hormonal fluctuations affect mood, and this is not something she can simply control
• Attending medical appointments when invited — it shows support and helps you understand the treatment plan
• Acknowledging the emotional burden — PCOS affects self-image, femininity, and can cause grief around fertility. Listen without trying to fix things.

• What is my PCOS phenotype and what does it mean for my treatment plan?
• Do I have insulin resistance? Should I take metformin?
• Which medication is best for my particular symptoms?
• Am I protecting my endometrium adequately?
• Should I be screened for diabetes or prediabetes? How often?
• Are GLP-1 medications an option for my situation?
• What is the evidence for inositol supplements in my case?
• Should I see a dermatologist for my skin and hair symptoms?
• How will my treatment change if I decide to try for a baby?

Symptoms of POI and early menopause result from declining estrogen levels and can include:

• Menstrual changes: Irregular, infrequent, or absent periods
• Vasomotor symptoms: Hot flashes, night sweats
• Vaginal and urinary symptoms: Dryness, discomfort during intercourse, recurrent urinary tract infections
• Mood changes: Depression, anxiety, irritability, difficulty concentrating
• Sleep disturbance: Insomnia, waking during the night
• Reduced libido
• Fatigue and joint pain

Symptoms can develop gradually or suddenly, depending on the cause. Women who experience abrupt POI (surgical or cancer-treatment-related) often have more severe symptoms initially.

HRT is the cornerstone of POI/early menopause management. Unlike HRT for natural menopause (which remains somewhat controversial), HRT for POI is strongly recommended by all major guidelines because it simply replaces hormones your body should be producing at your age.

Recommended regimens:

• Estrogen: Transdermal 17β-estradiol (patches or gel, typically 100 mcg/day) is preferred over oral estrogen because it has a better cardiovascular and clot risk profile. Oral 17β-estradiol (2 mg/day) is an alternative.
• Progesterone: Required if you have a uterus, to protect against endometrial overgrowth. Options include micronized progesterone (Prometrium, 200 mg/day for 12–14 days per cycle, or 100 mg daily continuously), medroxyprogesterone acetate, or a hormonal IUD (Mirena).
• Alternative: Combined oral contraceptive pills provide both estrogen and progestin and may be preferred by younger women who also want contraception (spontaneous ovulation can occur in POI). However, transdermal estradiol + progesterone is considered physiologically superior.

Duration: Continue until at least age 50–52, then reassess as you would for natural menopause.

What about breast cancer risk? In women with POI, HRT does not increase breast cancer risk above what women with functioning ovaries already have. You are simply maintaining the estrogen levels your body would normally produce. This is fundamentally different from HRT in women who have gone through natural menopause.

Estrogen is essential for maintaining bone density. Women with POI who do not take HRT lose bone rapidly and face a significantly increased risk of osteoporosis and fractures, even in their 30s and 40s.

• Baseline DEXA scan should be done at diagnosis
• Follow-up DEXA every 2–5 years while on HRT
• Calcium intake: 1,000–1,200 mg daily (diet + supplement if needed)
• Vitamin D: 1,000–2,000 IU daily (target blood level 30–50 ng/mL)
• Weight-bearing exercise: Walking, jogging, dancing, resistance training — at least 30 minutes most days
• Avoid smoking and excessive alcohol — both accelerate bone loss

Adequate HRT is the most important bone-protective intervention for women with POI.

Women with POI have a 1.5–2 times higher risk of cardiovascular disease compared to women who undergo natural menopause at the expected age. This is driven by premature estrogen deficiency, which affects cholesterol, blood vessel function, and insulin sensitivity.

• HRT is the primary cardiovascular protection — it reduces this excess risk when started at diagnosis and continued until age ~51
• Regular cardiovascular screening: Blood pressure, lipid panel, and glucose/HbA1c at least annually
• Heart-healthy lifestyle: Mediterranean-style diet, regular exercise, maintaining healthy weight, no smoking
• Manage additional risk factors aggressively (hypertension, diabetes, high cholesterol)

A POI diagnosis often triggers profound grief — grief over lost fertility, premature aging, changed identity, and an unexpected health burden. These feelings are valid and normal.

• Allow yourself to grieve. The loss of expected fertility and the shock of early menopause are significant life events.
• Seek professional support. Counseling or therapy (particularly cognitive behavioral therapy) can help process grief and manage anxiety or depression.
• Connect with others. Support groups (online and in-person) provide community with women who understand. The Daisy Network (UK) and POI support organizations offer resources.
• Tell your doctor about mood changes. Depression and anxiety can be both psychological and hormonal in POI. HRT itself often improves mood. Additional medication may be appropriate.

• What caused my POI? Should I have genetic or autoimmune testing?
• What HRT regimen do you recommend, and why?
• Is transdermal estrogen safer for me than oral?
• How long should I stay on HRT?
• What are my options for fertility? Is egg donation or embryo adoption possible?
• Should I have a bone density scan now?
• How will you monitor my cardiovascular risk?
• Can you refer me to a counselor or support group?
• If I have an FMR1 premutation, what does that mean for my family members?

Vasomotor symptoms (VMS) — hot flashes and night sweats — in premature ovarian insufficiency are often more severe and more frequent than in women going through natural menopause at 50+. This is because the estrogen drop in POI is typically abrupt rather than gradual, and occurs when the hypothalamic thermoregulatory system has not yet had time to adapt. Understanding why VMS occur and how both hormonal and non-hormonal options work helps you make informed treatment decisions.

Why hot flashes happen: Estrogen normally modulates the hypothalamic thermostat. When estrogen drops sharply, neurons in the hypothalamus (specifically KNDy neurons producing kisspeptin, neurokinin B, and dynorphin) become dysregulated, causing episodic firing that triggers peripheral vasodilation, sweating, and the subjective sensation of heat. In POI, this dysregulation occurs at an age when the brain is still hormonally calibrated to premenopausal estrogen levels — which is why VMS in POI are often more intense than in older menopausal women.

Why adequate HRT is the first and most important VMS treatment: For women with POI, HRT addresses VMS at the root cause rather than symptomatically. Adequate transdermal estradiol (100 mcg/24h equivalent) typically reduces hot flash frequency by 80–90%. If your VMS are not well controlled on your current HRT regimen, the first step is optimizing the dose — not adding a second drug. Many women are under-dosed on HRT (using menopause-level doses of 50 mcg/24h when POI requires 100 mcg/24h or higher). Raise this with your physician specifically: “My hot flashes are still frequent — should my estradiol dose be higher for POI?”

When non-hormonal options are needed: Non-hormonal VMS treatments are appropriate when:

• HRT is contraindicated (personal or strong family history of hormone-sensitive breast cancer; active VTE; certain liver conditions)
• The woman prefers to avoid hormonal treatment (autonomy and personal preference are valid)
• VMS persist despite optimized HRT and adding a non-hormonal adjunct is being considered

Important: non-hormonal VMS treatments do NOT provide bone protection, cardiovascular protection, or urogenital protection that HRT provides in POI. For women with POI who choose non-hormonal VMS management, additional interventions (antiresorptives for bone, cardiovascular risk monitoring, local vaginal estrogen for urogenital symptoms) must be discussed separately with a physician.

Non-hormonal VMS options with documented evidence:

• Fezolinetant (Veozah): First FDA-approved (May 2023) non-hormonal treatment for moderate-to-severe VMS due to menopause. Mechanism: neurokinin-3 (NK3) receptor antagonist that directly targets the hypothalamic KNDy pathway driving VMS. Dose: 45 mg once daily. Efficacy: SKYLIGHT trials showed 60–70% reduction in hot flash frequency vs. 30-35% for placebo at 12 weeks. Important: boxed warning for serious liver injury (transaminase elevation) added December 2024 — liver function tests required before starting and periodically during treatment; avoid in severe hepatic impairment. Not a substitute for HRT in POI from a systemic protection standpoint.
• Elinzanetant (Lynkuet): Dual NK1/NK3 receptor antagonist. FDA-approved October 24, 2025; EU approved November 17, 2025 (EC marketing authorization); UK approved July 8, 2025. Dose: 60 mg once daily. OASIS trials showed 60–70% reduction in hot flash frequency (the 120 mg OASIS trial dose is NOT the approved dose). Similar NK3 mechanism to fezolinetant; no hepatotoxicity signal in trials but LFT monitoring recommended per label.
• SSRIs/SNRIs (off-label for VMS): Paroxetine 7.5 mg (brand Brisdelle) is FDA-approved for VMS specifically; venlafaxine 37.5–75 mg, desvenlafaxine 50–100 mg, and escitalopram 10–20 mg have supportive evidence. Efficacy 40–60% reduction in hot flash frequency (less than hormonal therapy or NK3 antagonists). Important caution: paroxetine and fluoxetine significantly inhibit CYP2D6, which metabolizes tamoxifen — avoid in PCOS/POI women on tamoxifen for breast cancer.
• Gabapentin/pregabalin (off-label): Gabapentin 300 mg three times daily reduces hot flash frequency and improves sleep. Evidence quality: moderate. Side effects: drowsiness, dizziness, weight gain. Suitable for women with concurrent neuropathic pain or anxiety where these properties are beneficial.
• Clonidine (off-label): Modest efficacy (20–40% reduction); primarily limited by side effects (hypotension, dry mouth, sedation). Reserved for situations where other options are contraindicated or unavailable.

Lifestyle measures for VMS: Wearing layered clothing; keeping the bedroom cool (below 67°F/19°C); using a cooling fan at night; identifying and avoiding triggers (caffeine, alcohol, spicy food, stress); regular aerobic exercise (reduces severity but not frequency of hot flashes in trials); mindfulness-based stress reduction (MBSR) reduces perceived hot flash distress in randomized trials (not frequency). These measures help but are rarely sufficient as standalone management for severe VMS in POI.

• Fezolinetant (Veozah): A first-in-class NK3-receptor antagonist, FDA-approved in May 2023 for moderate-to-severe hot flashes due to menopause. It works on the brain’s temperature-control center — not hormones. Important safety: it carries an FDA Boxed Warning (added December 2024) for rare but serious liver injury; your doctor will check liver blood tests before you start, monthly for the first 2 months, and again at 3, 6, and 9 months. Tell your doctor right away about nausea, dark urine, yellowing of the skin/eyes, or right-upper-belly pain.
• Elinzanetant (Lynkuet): A newer dual NK1/NK3-receptor antagonist, FDA-approved in October 2025 for moderate-to-severe hot flashes due to menopause (also approved in the EU (November 2025), UK, Canada, and Australia). Another hormone-free option.
• Low-dose paroxetine (Brisdelle, 7.5 mg) and other SSRIs/SNRIs (e.g., venlafaxine, desvenlafaxine, escitalopram) — FDA-approved (paroxetine) or widely used to reduce hot flashes.
• Gabapentin (especially for night-time hot flashes) and oxybutynin are additional non-hormonal options; cognitive behavioral therapy (CBT) and clinical hypnosis also help.

Note for breast-cancer survivors: avoid strong CYP2D6-inhibiting SSRIs (paroxetine, fluoxetine) if you take tamoxifen, as they can reduce its effectiveness — venlafaxine or a NK-antagonist may be preferred. Discuss options with your oncology and menopause specialists.

Genitourinary syndrome of menopause (GSM) — the umbrella term for vaginal, urinary, and sexual symptoms caused by low estrogen — is frequently underdiagnosed and undertreated in women with POI. Because it develops in younger women, it is rarely associated with menopause by patients or their physicians, leading to significant delays in diagnosis and treatment. PCOS women do not typically develop GSM unless they also have low estrogen (rare in PCOS alone), but pelvic floor dysfunction and sexual health concerns are relevant to both conditions.

GSM symptoms in POI (caused by urogenital estrogen deficiency):

• Vaginal dryness and thinning of vaginal walls (atrophy)
• Dyspareunia (pain during sexual intercourse), often from reduced lubrication and tissue fragility
• Vaginal discharge or spotting from thinned epithelium
• Urinary urgency, frequency, and urge incontinence (from urethral thinning and reduced bladder neck support)
• Recurrent urinary tract infections (from reduced glycogen in the vaginal epithelium, which disrupts protective lactobacillus flora)
• Reduced genital sensation and orgasm intensity
• Reduced libido (from both testosterone changes and the psychological impact of painful sex)

Why GSM is often progressive without treatment: Unlike vasomotor symptoms, which often improve over time even without treatment, GSM does not resolve spontaneously. The vaginal and urinary tissues continue to thin and atrophy without estrogen stimulation. Women who delay treatment often experience worsening dyspareunia and urinary symptoms, and the tissue changes become progressively more difficult to reverse. Starting treatment at first symptoms is substantially more effective than waiting until symptoms are severe.

Treatment options for GSM in POI:

• Systemic HRT (first step in POI): Adequate systemic HRT (transdermal estradiol 100+ mcg/24h) provides significant urogenital benefit for most women with POI. If you are already on systemic HRT and still experiencing vaginal or urinary symptoms, local vaginal estrogen should be added — systemic doses required for adequate vaginal tissue estrogen levels are often higher than the systemic HRT dose alone achieves
• Local vaginal estrogen (for all POI women with urogenital symptoms):
  • Vaginal estradiol cream (e.g., Estrace): 0.5 g applicator 3 times/week for maintenance after initial loading phase
  • Vaginal estradiol tablet/insert (Vagifem/Yuvafem): 10 mcg nightly ×2 weeks, then twice weekly
  • Vaginal estradiol ring (Estring): 7.5 mcg/24h ring, replaced every 90 days; low systemic absorption; convenient for compliance
  • All vaginal estrogen products have minimal systemic absorption at maintenance doses. They do NOT substitute for systemic HRT for bone, cardiovascular, or vasomotor protection in POI
• Ospemifene (Osphena): Oral SERM (selective estrogen receptor modulator), 60 mg daily, FDA-approved for moderate-severe dyspareunia due to menopause. Estrogen-agonist effect in vaginal tissue without vaginal estrogen. Estrogen-antagonist in breast tissue (potential advantage in women with breast cancer history, though not routinely recommended in this group without oncology guidance). May cause hot flashes (estrogen-antagonist hypothalamic effect).
• Dehydroepiandrosterone/prasterone (Intrarosa): Vaginal DHEA insert, 6.5 mg nightly. DHEA locally converts to both estradiol and testosterone in vaginal tissue. FDA-approved for dyspareunia. Useful option for women who prefer non-estrogen labeling despite local conversion to estrogen.
• Lubricants and moisturizers: Non-hormonal products provide comfort but do not reverse tissue changes. Vaginal moisturizers (Replens, Hyalo Gyn) used every 2–3 days reduce friction and improve pH; water-based or silicone-based lubricants used during sexual activity reduce discomfort. These are useful adjuncts during treatment dose optimization but not substitutes for hormonal therapy when tissue atrophy is established.

Pelvic floor dysfunction in PCOS: While estrogen deficiency is less common in PCOS, pelvic floor dysfunction is not: women with PCOS have higher rates of vulvodynia (vulvar pain), interstitial cystitis, and pelvic floor hypertonicity (too much muscle tension) contributing to dyspareunia. If you experience pelvic pain or pain with sex that does not respond to standard PCOS management, ask for referral to a pelvic floor physiotherapist — this is a highly effective, underused specialty for both conditions.

PCOS-related infertility is primarily caused by absent or irregular ovulation. Treatment follows a stepwise approach:

1. Pre-conception optimization: Folic acid supplementation (at least 400 mcg daily), optimizing weight (5–10% loss if overweight), managing blood sugar, and screening for thyroid dysfunction.
2. First-line — Letrozole: 2.5–7.5 mg daily on cycle days 3–7. Letrozole (an aromatase inhibitor) induces ovulation with a lower risk of multiple pregnancy compared to clomiphene. Cumulative live birth rates are approximately 28% over up to ~5 treatment cycles in PCOS (PPCOS II). Covered by most insurance; used off-label for ovulation induction.
3. Second-line — Clomiphene or gonadotropins: Clomiphene citrate (50–150 mg, days 3–7) remains an option if letrozole is not available or not tolerated. Low-dose gonadotropin injections (FSH) use a “step-up” protocol to minimize the risk of ovarian hyperstimulation (OHSS), which is higher in PCOS.
4. Third-line — IVF (in vitro fertilization): Recommended when first-line and second-line treatments have not succeeded after 3–6 cycles, or when there are additional fertility factors. PCOS patients respond well to IVF but have a higher risk of OHSS. Modern protocols use GnRH antagonists and GnRH agonist triggers to virtually eliminate severe OHSS.
5. Surgical option — Laparoscopic ovarian drilling: Rarely used today but may be considered when medications are not effective or accessible. It can restore ovulation for 6–12 months.

Metformin may be added alongside ovulation induction to improve success rates, particularly in women with insulin resistance or higher BMI.

Fertility with POI is more challenging because the fundamental issue is a diminished or absent egg supply. However, options exist:

• Spontaneous conception: Occurs in approximately 5–10% of women with POI, even years after diagnosis. Ovarian function can fluctuate unpredictably. If you don’t want to become pregnant, use contraception.
• Oocyte (egg) donation: The most successful fertility option for women with POI, with pregnancy rates of 40–50% per cycle. Uses eggs from a donor fertilized with the partner’s sperm and transferred to the patient’s uterus.
• Embryo donation/adoption: Uses donated embryos from other couples’ IVF cycles.
• Fertility preservation (if POI is anticipated): Women at risk of POI (e.g., before cancer treatment, FMR1 premutation carriers, family history) may benefit from oocyte cryopreservation (egg freezing) while ovarian function remains.
• Surrogacy and adoption: These are paths to parenthood that some families choose.

Important: Continue HRT even during fertility treatment. Your reproductive endocrinologist will coordinate your hormone regimen with your fertility protocol.

Women with PCOS have higher rates of certain pregnancy complications:

• Gestational diabetes (GDM): 2–3 times more likely. Early glucose screening recommended.
• Preeclampsia: Higher risk, particularly with obesity or insulin resistance.
• Preterm birth: Modestly increased risk.
• Cesarean delivery: Higher rate, partly related to larger birth weight babies.

With good pre-conception management (optimizing weight, blood sugar, and blood pressure) and careful prenatal monitoring, most PCOS pregnancies result in healthy outcomes.

Women with POI who conceive via donor eggs are also at increased risk of hypertensive disorders and may need additional monitoring during pregnancy.

Fertility treatment is emotionally and physically demanding. Partners and family members play a crucial role:

• Attend appointments together when possible — fertility decisions should be shared
• Understand the timeline. Fertility treatment takes time. Multiple cycles may be needed. Manage expectations together.
• Be present emotionally. Each negative test is a loss. Acknowledge the grief rather than jumping to “next time.”
• Help with logistics: Medication schedules, injection preparation, appointment calendars
• Take care of yourself too. Fertility struggles affect both partners. Individual or couples counseling can help.
• Be open to all paths to parenthood. Donor eggs, embryo adoption, surrogacy, and adoption are all valid and beautiful paths to family building.

• What is my ovarian reserve (AMH level and antral follicle count)?
• Why are you recommending letrozole/clomiphene/IVF for my situation?
• What are my chances of conceiving with each treatment option?
• What is my risk of OHSS, and how will it be managed?
• Should I take metformin alongside ovulation induction?
• If I have POI, should I consider egg donation? What is the success rate?
• Should I consider freezing my eggs now for future use?
• What monitoring do I need during pregnancy given my condition?
• Can you recommend a fertility counselor or support group?

Up to 70–80% of women with PCOS have some degree of insulin resistance, regardless of body weight. This is a fundamental feature of the condition, not just a consequence of weight.

Screening recommendations (2023 guidelines):

• Oral glucose tolerance test (OGTT) at diagnosis — preferred over fasting glucose alone because it detects impaired glucose tolerance that fasting glucose misses
• Repeat OGTT every 1–3 years depending on risk factors
• HbA1c can be used for monitoring but may underestimate risk in PCOS
• Screen earlier and more frequently if BMI >25, family history of diabetes, age >40, or history of gestational diabetes

Management: Lifestyle modification (diet + exercise) is first-line. Metformin is recommended when lifestyle alone is insufficient. GLP-1 receptor agonists are emerging as powerful tools for weight and metabolic management in PCOS with obesity.

Women with PCOS have increased rates of:

• Dyslipidemia (abnormal cholesterol — high LDL, low HDL, high triglycerides)
• Hypertension
• Subclinical atherosclerosis (thickening of artery walls even in young women)
• Higher rates of cardiovascular events later in life

Women with POI who are not on HRT face additional cardiovascular risk from premature estrogen deficiency.

Recommended monitoring:

• Blood pressure at every visit
• Lipid panel at diagnosis and then every 1–2 years
• Waist circumference (abdominal obesity is a stronger risk marker than BMI alone)
• Assessment of cardiovascular risk using standard calculators, modified for PCOS risk

Obstructive sleep apnea (OSA) is significantly more common in women with PCOS, even independent of obesity. It worsens insulin resistance, fatigue, mood, and cardiovascular risk.

• Screen for symptoms: loud snoring, witnessed apneas, excessive daytime sleepiness, morning headaches
• Use validated questionnaires (e.g., STOP-BANG)
• Refer for sleep study if clinical suspicion is present
• Treatment with CPAP improves insulin sensitivity and cardiovascular markers

NAFLD is 2–5 times more common in women with PCOS, driven by insulin resistance. It is often asymptomatic but can progress to liver inflammation (NASH) and fibrosis.

• Liver enzymes (ALT, AST) should be checked periodically
• Ultrasound or FibroScan if elevated enzymes or clinical suspicion
• Management: weight loss (even 5–7%), exercise, and treating insulin resistance

• Do I have insulin resistance, and what test was used to determine this?
• Should I have an OGTT rather than just a fasting glucose test?
• What is my cardiovascular risk, and how should we monitor it?
• Should I be screened for sleep apnea or fatty liver disease?
• What are my lipid levels, and do I need treatment?
• How can I reduce my long-term risk of diabetes and heart disease?
• Should I see an endocrinologist or cardiologist?

Women with PCOS are 3–5 times more likely to experience depression and anxiety compared to the general population. In POI, rates of depression and anxiety are also significantly elevated, driven by both hormonal changes and the emotional impact of diagnosis.

Contributing factors include:

• Hormonal imbalances (androgen excess in PCOS, estrogen deficiency in POI)
• Insulin resistance (affects brain neurotransmitter function)
• Chronic inflammation
• Visible symptoms that affect self-image (acne, hirsutism, weight gain, hair loss)
• Fertility grief and uncertainty
• The chronic, ongoing nature of the condition

Treatment options:

• Cognitive behavioral therapy (CBT) — strong evidence for both depression and anxiety in PCOS
• Mindfulness-based approaches
• Antidepressant medication when appropriate (SSRIs are generally safe with PCOS medications)
• For POI: HRT itself often improves mood significantly
• Exercise — has antidepressant effects comparable to medication in mild-to-moderate depression

PCOS-related symptoms — weight gain, acne, unwanted hair growth, scalp hair loss — directly affect how women feel about their bodies. This can lead to:

• Poor body image and reduced self-esteem
• Social withdrawal and avoidance of activities (swimming, intimate relationships)
• Disordered eating patterns, including restrictive dieting, binge eating, or emotional eating
• Women with PCOS are at higher risk of binge eating disorder and bulimia

Healthcare providers should screen for eating disorders before recommending weight loss. Dietary advice should be delivered sensitively, focusing on health behaviors rather than numbers on a scale.

Both PCOS (difficulty conceiving) and POI (potential loss of the ability to conceive with your own eggs) can cause profound grief around fertility. This grief is real and deserves recognition, even if you ultimately build your family through treatment or alternative paths.

• Grief can be triggered by the diagnosis itself, failed treatment cycles, seeing others’ pregnancies, or insensitive questions about family plans
• Couples counseling or individual therapy with a fertility-aware therapist can be invaluable
• Support groups (RESOLVE: The National Infertility Association, PCOS Challenge) provide community
• Consider consulting a reproductive psychologist alongside your fertility team

• Build a healthcare team you trust. A gynecologist or reproductive endocrinologist who understands PCOS/POI, a primary care provider for metabolic monitoring, a mental health professional, and potentially a dietitian who specializes in PCOS.
• Track your symptoms. Use a period tracker, note mood changes, energy levels, and symptom patterns. This data helps you and your doctor optimize your treatment.
• Move your body regularly. Find exercise you enjoy — it doesn’t have to be intense. Walking, swimming, yoga, dancing, resistance training all benefit PCOS and POI.
• Prioritize sleep. Aim for 7–9 hours. Address sleep apnea if present. Establish consistent sleep routines.
• Connect with community. Online and local support groups reduce isolation. Hearing from women who understand your experience is powerful.
• Advocate for yourself. If your doctor minimizes your symptoms, seek another opinion. You deserve comprehensive, respectful care.

• Understand that mood changes are often hormonally driven, not a choice or a personality issue
• Avoid minimizing her experience (“just relax,” “it could be worse,” “at least you’re healthy”)
• Encourage professional help without pressuring — “I’m here for you, and I think a counselor could also help”
• Be aware of your own mental health needs. Supporting someone through chronic illness is taxing.
• Learn about the condition so she doesn’t have to educate you while managing her own health

• Can you screen me for depression and anxiety today?
• Should I be assessed for disordered eating before we discuss weight management?
• Can you refer me to a therapist who understands PCOS/POI?
• Could my mood changes be related to my hormonal treatment?
• Are there support groups you recommend for my condition?
• How does exercise affect my mood, and what type is best?
• If I need an antidepressant, will it interact with my PCOS/POI medications?

• PCOS Challenge: The National Polycystic Ovary Syndrome Association — largest PCOS patient support organization in the US; education, advocacy, and community
• RESOLVE: The National Infertility Association — support groups, education, and advocacy for all causes of infertility (including PCOS and POI)
• The Daisy Network (UK) — leading POI support charity with educational resources and peer support
• The International Premature Ovarian Insufficiency Association — global resources and support for women with POI
• PCOSAA (PCOS Awareness Association) — education and awareness campaigns
• Endocrine Society Patient Resources — reliable medical information on hormonal conditions

• University of Utah Reproductive Endocrinology and Infertility Division — comprehensive care for PCOS and POI, fertility treatment, clinical research participation. Academic medical center with specialists in complex hormonal conditions.
• Utah Center for Reproductive Medicine — full-service fertility clinic offering IVF, oocyte cryopreservation (egg freezing), donor egg programs, and fertility preservation. Locations along the Wasatch Front.
• Intermountain Health Women’s Services and Endocrinology — endocrinology clinics with expertise in PCOS metabolic management, diabetes prevention, and thyroid disorders. Multiple locations throughout Utah.
• Intermountain Fertility Center — fertility services including ovulation induction, IUI, and IVF with PCOS-specific protocols
• University of Utah Genetic Counseling — for POI patients needing genetic evaluation (karyotype, FMR1 testing) and family counseling

Note: Verify current contact details and insurance acceptance directly with each institution. Services, locations, and providers may change.

• 988 Suicide and Crisis Lifeline: Call or text 988 (available 24/7)
• Crisis Text Line: Text HOME to 741741
• Postpartum Support International: 1-800-944-4773 (for perinatal mood disorders, including after fertility treatment)
• NAMI (National Alliance on Mental Illness): Information, support groups, and referrals
• Psychology Today therapist finder: Filter by specialty (infertility, women’s health, chronic illness) and location

• Monash University PCOS Guideline: The 2023 International Evidence-Based Guideline is freely available online with patient-focused resources
• ACOG (American College of Obstetricians and Gynecologists): Patient education materials on PCOS, fertility, and menopause
• Endocrine Society: Hormone Health Network patient resources
• ESHRE (European Society of Human Reproduction and Embryology): POI guideline and patient information
• UpToDate Patient Education: Detailed, doctor-reviewed articles on PCOS and POI (some free, some subscription)

Caution about online information: Be wary of social media influencers, unregulated supplement sellers, and “cure” claims. Neither PCOS nor POI can be cured, but both can be effectively managed. Stick to evidence-based sources and discuss any new information with your healthcare team.

PCOS and POI are global conditions with some important regional variations:

• Southeast Asian and South Asian populations have higher PCOS prevalence and metabolic risk, including the “lean PCOS” phenotype common in South Asian women
• Middle Eastern and North African populations have very high PCOS prevalence, with cultural factors sometimes delaying diagnosis
• Japan uses modified diagnostic criteria (JSOG 2024) with different testosterone thresholds for East Asian populations
• Europe leads in inositol research and transdermal HRT protocols for POI
• China has extensive research on TCM-integrated PCOS approaches. While acupuncture + letrozole combinations have been studied in large RCTs, the landmark PCOSAct trial showed no significant difference in live birth rates with acupuncture alone. Only well-designed RCT evidence is included in this guide.
• Fertility treatment access and protocols vary enormously by country due to regulation, cost, and cultural factors. International patients should verify local availability of recommended treatments.

DE-ADOPTED

What it was: A surgical procedure in which a wedge-shaped piece of ovarian tissue was removed to reduce androgen production and restore ovulation. Introduced in 1935 by Stein and Leventhal and was the original treatment for PCOS.

Why it was abandoned: Caused extensive pelvic adhesions (scar tissue) that often worsened infertility. Replaced by laparoscopic ovarian drilling (LOD) in the 1980s, which itself has been largely superseded by letrozole-based ovulation induction. LOD is now considered a second- or third-line option only when medical therapy fails.

DE-ADOPTED (downgraded to second-line)

What it was: Clomiphene citrate was the standard first-line fertility medication for PCOS for over 40 years.

Why it was downgraded: The PPCOS II trial (Legro et al., NEJM 2014) demonstrated that letrozole produced significantly higher live birth rates than clomiphene (27.5% vs. 19.1%) with a lower multiple pregnancy rate. The 2023 International Evidence-Based PCOS Guidelines now recommend letrozole as first-line. Clomiphene remains a valid second-line option, particularly where letrozole is unavailable or contraindicated.

FAILED

What it was: Acupuncture was proposed as a standalone treatment to improve ovulation rates in women with PCOS, based on small preliminary studies suggesting hormonal effects.

Why it failed: The large, well-designed PCOSAct trial (Wu et al., JAMA 2017; NCT01573858) randomized 1,000 women across 27 sites and found that acupuncture did not significantly improve live birth rates compared to sham acupuncture plus clomiphene or clomiphene alone. While acupuncture may have a role in general wellbeing, the evidence does not support it as a standalone fertility treatment for PCOS.

WITHDRAWN (largely abandoned for PCOS)

What they were: Insulin-sensitizing drugs (TZDs) that were studied as alternatives to metformin for treating insulin resistance in PCOS. Rosiglitazone (Avandia) and pioglitazone (Actos) both showed some benefits for insulin sensitivity and androgen levels.

Why they were abandoned: Rosiglitazone was found to increase cardiovascular risk (heart attack) and received FDA restrictions in 2010. While pioglitazone remains available for type 2 diabetes, it causes weight gain and edema — problematic side effects for PCOS patients. Both have been superseded by metformin and now GLP-1 receptor agonists as preferred insulin-sensitizing strategies in PCOS.

WITHDRAWN (largely abandoned due to hepatotoxicity)

What it was: A non-steroidal anti-androgen that was studied for treating hirsutism and acne in PCOS. It directly blocks androgen receptors and showed efficacy in reducing androgen-driven symptoms.

Why it was abandoned: Reports of serious liver toxicity (hepatotoxicity), including fatal hepatic failure, led to its withdrawal from PCOS use in most countries. Spironolactone, which has a much better safety profile, is now the preferred anti-androgen for PCOS-related hirsutism and acne in North America. In Europe, cyproterone acetate (at low doses) is also used.

DE-ADOPTED

What it was: Supraphysiologic doses of estrogen (such as ethinyl estradiol 50+ mcg) were previously used for hormone replacement in young women with POI, often via high-dose combined oral contraceptives.

Why it was de-adopted: The 2024 ESHRE/ASRM/IMS POI guideline recommends physiologic hormone replacement (transdermal 17β-estradiol 100 mcg/day or equivalent) rather than supraphysiologic dosing. High-dose ethinyl estradiol increases thromboembolic risk and does not provide the bone-protective benefits of transdermal estradiol. Physiologic replacement better mimics natural ovarian function and has a superior cardiovascular safety profile.

FAILED

What it was: Low-dose dexamethasone or prednisone was sometimes added to clomiphene for women with PCOS and elevated adrenal androgens (DHEA-S) who failed to ovulate with clomiphene alone.

Why it failed: Evidence from controlled trials showed inconsistent benefits and potential harms including weight gain, glucose intolerance, and bone density reduction with prolonged use. The 2023 International Evidence-Based PCOS Guidelines do not recommend routine glucocorticoid use for ovulation induction. Switching to letrozole or gonadotropins is the preferred approach for clomiphene-resistant PCOS.

• AMH (anti-Müllerian hormone) — a blood marker produced by small ovarian follicles. It reflects ovarian reserve (the remaining egg supply). High AMH suggests PCOS; very low or undetectable AMH suggests POI or diminished reserve.
• Anovulation — absence of ovulation (the release of an egg from the ovary). A hallmark of PCOS and a direct cause of irregular or absent periods and infertility.
• Clomiphene (clomiphene citrate) — an oral medication that stimulates ovulation by blocking estrogen receptors in the brain, causing the pituitary to release more FSH and LH. Once the standard first-line fertility drug for PCOS; now second-line after letrozole.
• DHEA-S (dehydroepiandrosterone sulfate) — an androgen produced mainly by the adrenal glands. Elevated levels can contribute to PCOS symptoms and help distinguish adrenal from ovarian sources of excess androgens.
• FSH (follicle-stimulating hormone) — a pituitary hormone that stimulates the ovaries to develop follicles and produce eggs. Elevated FSH (>25 IU/L) is a key diagnostic criterion for POI; the 2024 ESHRE/ASRM/IMS guideline allows the diagnosis on a single elevated result (a repeat or AMH may be used when uncertain).
• Hirsutism — excess hair growth in a male-pattern distribution (face, chest, abdomen, back) caused by elevated androgens. Assessed using the modified Ferriman-Gallwey score.
• HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) — a calculation using fasting glucose and fasting insulin levels to estimate insulin resistance. Higher values indicate greater resistance. Commonly used in PCOS evaluation.
• HRT (hormone replacement therapy) — treatment that replaces estrogen (and progesterone if the uterus is present) to manage symptoms and prevent long-term complications of estrogen deficiency. Medically necessary in POI until the natural age of menopause.
• Hyperandrogenism — excess levels or effects of androgens (male hormones such as testosterone). Can be clinical (visible symptoms like hirsutism, acne, hair thinning) or biochemical (elevated androgen levels on blood tests). A core feature of PCOS.

• Insulin resistance — a condition in which the body’s cells respond poorly to insulin, requiring the pancreas to produce more to maintain normal blood sugar. Affects 70–80% of women with PCOS and drives metabolic complications including type 2 diabetes risk.
• IVF (in vitro fertilization) — a fertility treatment in which eggs are retrieved from the ovaries, fertilized with sperm in a laboratory, and the resulting embryo is transferred to the uterus. Third-line treatment for PCOS; the primary fertility option for POI (using donor eggs).
• Letrozole — an aromatase inhibitor that blocks estrogen production, causing the brain to increase FSH release and stimulate ovulation. Now the recommended first-line fertility medication for PCOS, with higher live birth rates and lower multiple pregnancy risk than clomiphene.
• LH (luteinizing hormone) — a pituitary hormone that triggers ovulation. In PCOS, LH levels are often elevated relative to FSH (high LH:FSH ratio), contributing to anovulation and excess androgen production.
• Oocyte cryopreservation (egg freezing) — a fertility preservation technique in which mature eggs are retrieved and frozen for future use. Important for women at risk of POI (e.g., before cancer treatment or in FMR1 premutation carriers).
• Oligomenorrhea — infrequent menstrual periods, typically defined as cycles longer than 35 days or fewer than 8 cycles per year. A common presentation of PCOS and sometimes an early sign of POI.

• PCOS (polycystic ovary syndrome) — a common hormonal condition affecting 8–13% of reproductive-age women. Characterized by a combination of irregular ovulation, excess androgens, and/or polycystic ovarian morphology. A lifelong metabolic and reproductive condition, not just a fertility problem.
• POI (premature ovarian insufficiency) — loss of normal ovarian function before age 40, resulting in irregular or absent periods, estrogen deficiency, and reduced fertility. Formerly called “premature ovarian failure” — the term was changed because ovarian function can fluctuate and spontaneous conception remains possible in 5–10% of cases.
• Rotterdam criteria — the internationally accepted diagnostic standard for PCOS, requiring at least two of three features: (1) irregular or absent ovulation, (2) clinical or biochemical hyperandrogenism, (3) polycystic ovarian morphology on ultrasound or elevated AMH. Other causes must be excluded. Endorsed by the 2023 International Evidence-Based PCOS Guidelines.

• University of Utah Health — Reproductive Endocrinology & Infertility Division — Academic medical center offering comprehensive PCOS and POI care, fertility treatment (IVF, ovulation induction, egg freezing), genetic counseling, and clinical trial access. Part of U of U Health’s Department of Obstetrics & Gynecology. Main line: 801-581-2121
• Intermountain Fertility Center — Full-service fertility clinic offering PCOS-specific ovulation induction protocols, IUI, IVF, donor egg programs, and oocyte cryopreservation. Multiple locations along the Wasatch Front. Main line: 801-442-2000
• Intermountain Health Endocrinology — Endocrinology clinics with expertise in PCOS metabolic management, insulin resistance, diabetes prevention, and thyroid disorders. Locations throughout Utah. Main line: 801-442-2000
• George E. Wahlen VA Medical Center — Women’s health clinic with gynecology, endocrinology referrals, and mental health services for eligible veterans. Phone: 801-582-1565
• Huntsman Mental Health Institute (HMHI) — Comprehensive mental health services including treatment for depression, anxiety, and adjustment to chronic illness. Phone: 801-583-2500

Note: Verify current contact details and insurance acceptance directly with each institution. Services, locations, and providers may change.

• Mayo Clinic — Reproductive Endocrinology & Infertility — Rochester, MN. Nationally recognized program for complex PCOS and POI cases, fertility preservation, and metabolic evaluation. Phone: 507-284-2511
• Cleveland Clinic — Reproductive Endocrinology & Infertility — Cleveland, OH. Comprehensive fertility and hormonal health services, including PCOS-specific programs and POI management. Phone: 216-444-2200
• UCSF — Reproductive Endocrinology & Infertility — San Francisco, CA. Academic program with expertise in complex hormonal disorders, fertility preservation, and cutting-edge research. Phone: 415-476-1000
• Massachusetts General Hospital — PCOS Center — Boston, MA. Dedicated multidisciplinary PCOS clinic with endocrinology, dermatology, nutrition, and mental health integration. Phone: 617-726-2000

• VA Women’s Health Services — The VA provides gynecological care, reproductive health services, and referrals for fertility treatment for eligible women veterans. Fertility services including IVF are available to veterans with service-connected conditions affecting fertility. National VA helpline: 1-800-827-1000
• George E. Wahlen VA Medical Center (Salt Lake City) — Women’s health clinic with gynecology, endocrinology referrals, and mental health services. Phone: 801-582-1565
• The VA can coordinate referrals to community-based reproductive endocrinology specialists through the Community Care program when specialty services are not available within the VA system.

• CFAS (Canadian Fertility and Andrology Society) — The national professional organization for reproductive medicine in Canada. CFAS maintains clinical practice guidelines, accredits fertility clinics, and provides a clinic finder for patients seeking PCOS and POI care across provinces.
• Mount Sinai Fertility — University of Toronto — Toronto, ON. Leading Canadian academic fertility program with PCOS and POI expertise, donor egg programs, and clinical research. Phone: 416-586-4800
• McGill University Health Centre — Reproductive Centre — Montreal, QC. Academic reproductive endocrinology program with expertise in complex hormonal disorders and fertility preservation. Phone: 514-934-1934
• UBC Centre for Reproductive Health — University of British Columbia — Vancouver, BC. Comprehensive reproductive endocrinology and fertility services with PCOS metabolic research programs. Phone: 604-875-2424
• Fertility treatment coverage varies by province. Ontario, Quebec, Manitoba, and New Brunswick offer some publicly funded IVF cycles. Letrozole and metformin are covered by most provincial drug formularies.

United Kingdom:

• University College London Hospital (UCLH) — Reproductive Medicine Unit — London. Major academic centre for PCOS, POI, and fertility treatment with active clinical research programs.
• Oxford Fertility — University of Oxford — Oxford. Academic fertility programme with expertise in PCOS ovulation induction and POI management.
• Verity — UK-based PCOS charity providing peer support, educational resources, and awareness campaigns.
• The Daisy Network — Leading UK POI support charity offering peer support, educational materials, and research advocacy.

Europe:

• Monash University PCOS Research Group — Melbourne, Australia. Led the development of the 2023 International Evidence-Based PCOS Guidelines. PCOS Alliance Australia provides national patient advocacy.
• Erasmus MC — Division of Reproductive Endocrinology & Infertility — Rotterdam, Netherlands. Birthplace of the Rotterdam criteria. Leading European centre for PCOS research and clinical care.
• Sapienza University of Rome — Reproductive Endocrinology — Rome, Italy. Major European centre for PCOS inositol research and metabolic management.
• ESHRE (European Society of Human Reproduction and Embryology) — Developed the 2024 POI guideline and maintains a network of certified fertility centres across Europe.

Japan / Asia-Pacific:

• St. Marianna University School of Medicine — Reproductive Medicine — Kawasaki, Japan. Major Japanese centre for PCOS research using JSOG 2024 criteria with population-specific testosterone thresholds.
• National University Hospital (NUH) — Reproductive Medicine — Singapore. Regional referral centre for complex reproductive endocrinology across Southeast Asia.

Letrozole is recommended as first-line for ovulation induction in PCOS by the 2023 International Evidence-Based Guidelines, the Endocrine Society, and ESHRE, based on superior live birth rates compared to clomiphene.

However, letrozole is used off-label for this indication in many countries. It was originally developed and approved as a breast cancer treatment. While its use for ovulation induction is well-established in clinical practice and strongly supported by evidence, regulatory approval for this specific indication varies:

• United States: Off-label use is standard practice and widely prescribed by reproductive endocrinologists
• Australia: TGA-approved for breast cancer; off-label for ovulation induction but recommended by national guidelines
• United Kingdom: NICE guidelines recommend letrozole as first-line; available through NHS fertility services
• Europe (EU): ESHRE recommends letrozole as first-line; availability and reimbursement vary by country
• Some countries have restricted or limited access to letrozole for fertility use due to regulatory frameworks that do not recognize off-label indications

If letrozole is not available in your country, clomiphene citrate remains an effective and widely available alternative.

Metformin is widely used in PCOS for insulin resistance and metabolic management, but guideline recommendations differ on when and how to use it:

• 2023 International Guidelines (Monash/NHMRC): Recommend metformin as an adjunct to lifestyle for metabolic features, or when oral contraceptives are contraindicated or not tolerated. Can be used alone or alongside other treatments.
• ESHRE/ASRM: Support metformin for metabolic benefits in PCOS, particularly for women with BMI >25 and insulin resistance. Also recognize a modest role in improving ovulation.
• Endocrine Society (US): Recommend metformin primarily for metabolic indications (prediabetes prevention) rather than as a first-line fertility treatment.
• NICE (UK): Recommend metformin for women with PCOS who have a BMI ≥25 and for ovulation induction (alone or with clomiphene) when letrozole is not available.

In practice, metformin is one of the most commonly prescribed medications globally for PCOS. It is inexpensive, widely available, and has a long safety record. Discuss with your doctor whether it is appropriate for your specific situation.

Myo-inositol (typically 4 g/day, often combined with D-chiro-inositol in a 40:1 ratio) is widely used internationally as a supplement for PCOS, particularly in Europe and Australia.

• Evidence: Moderate-quality evidence supports benefits for insulin sensitivity, ovulation, and androgen levels. European research groups have been particularly active in studying inositol for PCOS.
• Guideline position: The 2023 International PCOS Guidelines recognize potential benefits but note that the overall evidence is not yet as strong as for metformin. They do not recommend against its use.
• Availability: Sold as a dietary supplement (not a prescription medication) in most countries. Quality and dosing can vary between products. Look for reputable manufacturers with standardized dosing.
• Safety: Generally well-tolerated with minimal side effects. Can be used alongside other PCOS treatments, though patients should inform their doctor about all supplements.

Inositol may be a reasonable option for women seeking a supplement-based approach to insulin resistance management in PCOS, especially if metformin is not tolerated. Discuss with your healthcare team.